ClinicalTrials.gg
CompletedNCT01957150Updated Apr 10, 2019Results posted

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

A Phase 4 interventional study of Fluticasone Furoate/Vilanterol and Vilanterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 45 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-04-10.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
12th of 25
283 · median 229
Started
2014
with 3 others
Phase 4
13 of 25
2 open now
Registered
7th of 25
by date
Lead sponsor
21 of 25
GlaxoSmithKline

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 4 that started in 2014, is one of 13 in phase 4, and was the 7th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, parallel-group study. The FF/VI inhalation powder once daily and VI inhalation powder once daily will be evaluated in subjects with COPD over 156 weeks. The primary objective of this study is to evaluate the effect of the inhaled corticosteroid FF on bone mineral density assessed at the total hip by comparing FF/VI treatment with VI treatment in subjects with moderate COPD.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : Subjects must give their signed and dated written informed consent to participate.
  • Gender: Male or female subjects. Female subjects must be or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of may be made at the discretion of the investigator in accordance with local practice in relation to adequate .
  • Age: >= 40 years of age at Screening (Visit 1)
  • diagnosis: Subjects with a clinical history of COPD in accordance with the following definition by the American Thoracic Society/European Respiratory Society: COPD is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
  • Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette smoking at screening (Visit 1). Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Number of pack years = (number of cigarettes per day/20) x number of years smoked Note: Pipe and/or cigar use cannot be used to calculate pack year history.
  • Severity of Disease: Subject with a measured post-albuterol/salbutamol (FEV1)/forced vital capacity (FVC) ratio of \<0.70 at Screening (Visit 1). Subjects with a measured post-albuterol/salbutamol 50% \<=FEV1 \<=70% of predicted normal values calculated using National Health and Nutrition Examination Survey (NHANES III) reference equations at Screening (Visit 1).
  • Native Hip: Have at least one evaluable native hip.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of ).
  • Alpha1-antitrypsin deficiency: Subjects with alpha-1 antitrypsin deficiency as the underlying cause of COPD.
  • Other respiratory disorders: Subjects with tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases.
  • Lung resection or transplantation: Subjects with lung volume reduction surgery within the 12 months prior to Screening Visit 1 or having had a lung transplant.
  • Chest X-ray: Subjects with a chest X-ray (or Computer Axial Tomography (CT) scan) that revealed evidence of abnormalities not believed to be due to the presence of COPD. A chest X-ray should be taken at Screening Visit 1 if a chest X-ray or CT scan is not available within 12 months prior to Visit 1.
  • Poorly controlled COPD: Subjects with poorly controlled COPD, defined as the occurrence of the following in the 12 weeks prior to Screening Visit 1: Acute worsening of COPD that is managed by the subject with or antibiotics or that requires treatment prescribed by a physician or requires hospitalization.
  • Moderate or severe COPD exacerbation or lower respiratory tract infection: Subjects with 2 or more moderate or severe COPD exacerbations and/or a lower respiratory tract infection (including pneumonia) within the 12 months prior to Screening Visit 1 or experience a moderate or severe COPD exacerbation and/or a lower respiratory infection (including pneumonia) during the Run-In period. NOTE: A moderate COPD exacerbation is defined as requiring systemic corticosteroids and/or antibiotics. A severe COPD exacerbation is defined as requiring hospitalization.
  • Abnormal clinically significant laboratory finding: Subjects who have an abnormal, clinically significant finding in any liver chemistry, biochemical, or haematology tests at Screening Visit 1 or upon repeat prior to randomization.
  • Abnormal and clinically significant 12-lead (ECG): Subjects who have an abnormal, clinically significant ECG finding at Screening Visit 1.
  • Non-Compliance during Run-In Period: Failure to demonstrate adequate compliance with run-in medication (\< 80% compliant), the ability to withhold COPD medications, and to keep clinic visit appointments.
  • Bone disorders/conditions: Subjects with historical or current evidence of bone cancer, severe scoliosis, rheumatoid arthritis, metabolic bone diseases (other than osteoporosis) including hyper-or hypo-parathyroidism, Paget's disease of bone, osteomalacia, or osteogenesis imperfecta. Removal of vertebrae between L1 and L4 of the lumbar spine and/or presence of metal implants or devices, such as plates, rods, or screws in the lumbar spine and/or hip.
  • Immobility: Wheel chair bound or paraplegic.
  • Low vitamin D: Previously known low-serum 25-hydroxy vitamin D concentration (less than 10ng [25nmoles] per liter).
  • Other diseases/abnormalities: Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study within the 3-year study.
  • Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
  • Drug/food allergy: Subjects with a history of to any of the study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate). In addition, patients with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded.
  • Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years.
  • Prohibited medications prior to spirometry at Visit 1: Subjects who are medically unable to withhold the following medications prior to spirometry testing at Visit 1
  • No use within 48 hours (hrs) prior to Visit 1 Spirometry Testing: Inhaled corticosteroids, Inhaled Inhaled Corticosteroids (ICS)/ long acting beta2-agonist (LABA) combination products, Long-acting anticholinergics (e.g., tiotropium), Theophylline preparations, Oral leukotriene inhibitors (zafirlukast, montelukast, zileuton), Oral PDE-4 inhibitors (e.g. roflumilast), Oral beta-agonists (Long-acting), Inhaled long acting beta2-agonist (LABA)-Indacaterol.
  • No use within 24 hrs prior to Visit 1 Spirometry Testing: Other inhaled LABAs (e.g., salmeterol), Inhaled sodium cromoglycate or nedocromil sodium.
  • No use within 12 hrs prior to Visit 1 Spirometry Testing: Oral beta-agonists (Short-acting).
  • No use within 4 hrs prior to Visit 1 Spirometry Testing: Ipratropium/ albuterol (salbutamol) combination product, Inhaled short-acting beta2-agonists, Short-acting anti-cholinergics (e.g., ipratropium bromide).
  • Additional medication: Use of the following medications within the following time intervals prior to Visit 1 or during the study (unless otherwise specified):
  • No use within 12 weeks prior to Screening Visit 1 or thereafter at any time during the study (unless otherwise specified): Depot corticosteroids.
  • No use within 30 days prior to Screening Visit 1 or thereafter at any time during the study (unless otherwise specified): Systemic, Oral, parenteral, intra-articular corticosteroids (Subjects may take courses of systemic corticosteroids, where necessary, for treatment of an exacerbation during the double-blind treatment period).
  • No use within 30 days or 5 half lives whichever is longer prior to Screening Visit 1 or thereafter at any time during the study (unless otherwise specified): Any other drug.
  • COPD medications: Use of ICS, long-acting beta2-agonists (LABA), or ICS/LABA combination products (other than the study-provided double-blind study medication) at Visit 2 (Randomization) or during the double-blind treatment period.
  • Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e., \<=12 hours per day) is not exclusionary.
  • Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
  • Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of to participate in the study.
  • Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
283 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate/Vilanterol 100/25 micrograms (mcg) QD

    Subjects will self administer FF/VI 100/25 mcg inhalation powder once daily for 156 weeks via the NDPI.

    Drug: Fluticasone Furoate/Vilanterol

  • Experimental
    Vilanterol 25 mcg QD

    Subjects will self administer VI 25 mcg inhalation powder once daily for 156 weeks via the NDPI.

    Drug: Vilanterol

Interventions

  • DrugFluticasone Furoate/Vilanterol

    Drug pages: Fluticasone furoate · Vilanterol

    Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.

  • Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Bone Mineral Density (BMD) Measured at Total Hip

    BMD analysis performed on log (BMD ratio to baseline) using a repeated measures model with covariates of treatment group, age, gender, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

    Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks

Secondary outcomes

  1. Percentage Change From Baseline in BMD Measurements at Total Hip by Gender (Male Participants)

    BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

    Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks

  2. Percentage Change From Baseline in BMD Measurements at Total Hip by Gender (Female Participants)

    BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

    Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks

  3. Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Male Participants)

    BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

    Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks

  4. Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Female Participants)

    BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

    Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks

  5. Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4)

    BMD analysis performed on log (BMD ratio to baseline) using a repeated measures model with covariates of treatment group, age, gender, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

    Time frame: Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks

07

Results

Posted Apr 10, 2019

Participant flow

The study was conducted on participants with chronic obstructive pulmonary disease (COPD) in five countries to assess the long-term safety effects of Fluticasone Furoate (FF) component of the FF/Vilanterol (VI) inhalation powder.

Participant flow — Overall Study
MilestoneParticipants Administered VIParticipants Administered FF/VI
Started142141
Completed8783
Not completed5558
Withdrew: Adverse event2320
Withdrew: Withdrawal by subject1317
Withdrew: Physician decision36
Withdrew: Lost to follow-up44
Withdrew: Protocol violation10
Withdrew: Lack of efficacy1111

Outcome measures

PrimaryPercentage Change From Baseline in Bone Mineral Density (BMD) Measured at Total Hip

BMD analysis performed on log (BMD ratio to baseline) using a repeated measures model with covariates of treatment group, age, gender, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

Time frame:
Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Reported as:
Least squares mean · Percentage change
Percentage Change From Baseline in Bone Mineral Density (BMD) Measured at Total Hip
Percentage changeParticipants Administered VIParticipants Administered FF/VI
Overall % change per year, n = 132, 1300.18 (-0.18 to 0.55)-0.27 (-0.63 to 0.09)
% change by Week 26, n= 130, 1300.37 (-0.07 to 0.82)0.31 (-0.13 to 0.76)
% change by Week 52, n = 104, 1210.35 (-0.21 to 0.91)-0.43 (-0.96 to 0.10)
% change by Week 78, n = 97, 1020.22 (-0.41 to 0.85)-0.68 (-1.29 to -0.07)
% change by Week 104, n = 94, 96-0.16 (-0.84 to 0.52)-1.02 (-1.68 to -0.36)
% change by Week 130, n = 88, 840.00 (-0.73 to 0.75)-1.02 (-1.75 to -0.29)
% change by Week 156, n = 76, 75-0.16 (-1.02 to 0.71)-1.29 (-2.13 to -0.45)
Statistical analysis
  • Participants Administered VI vs Participants Administered FF/VI · Percentage change from baseline: -0.46 · 95% CI -0.97 to 0.06Treatment comparison for overall weeks
SecondaryPercentage Change From Baseline in BMD Measurements at Total Hip by Gender (Male Participants)

BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

Time frame:
Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Reported as:
Least squares mean · Percent change
Percentage Change From Baseline in BMD Measurements at Total Hip by Gender (Male Participants)
Percent changeParticipants Administered VIParticipants Administered FF/VI
Overall Week % change per year, n = 67, 630.27 (-0.23 to 0.77)-0.20 (-0.70 to 0.31)
% change by Week 26, n = 66, 630.45 (-0.06 to 0.97)0.44 (-0.09 to 0.97)
% change by Week 52, n = 52, 560.48 (-0.31 to 1.27)-0.43 (-1.19 to 0.33)
% change by Week 78, n = 51, 460.06 (-0.81 to 0.95)-0.68 (-1.56 to 0.21)
% change by Week 104, n = 50, 430.07 (-0.86 to 1.00)-0.68 (-1.62 to 0.27)
% change by Week 130, n = 44, 390.37 (-0.75 to 1.50)-0.89 (-2.02 to 0.26)
% change by Week 156, n = 40, 350.05 (-1.26 to 1.37)-1.39 (-2.71 to -0.05)
Statistical analysis
  • Participants Administered VI vs Participants Administered FF/VI · Percentage change from baseline: -0.47 · 95% CI -1.17 to 0.24Overall Weeks for Male
SecondaryPercentage Change From Baseline in BMD Measurements at Total Hip by Gender (Female Participants)

BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

Time frame:
Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Reported as:
Least squares mean · Percent change
Percentage Change From Baseline in BMD Measurements at Total Hip by Gender (Female Participants)
Percent changeParticipants Administered VIParticipants Administered FF/VI
OverallWeek % change per year, n = 65, 670.09 (-0.46 to 0.64)-0.31 (-0.84 to 0.22)
% change by Week 26, n = 64, 670.28 (-0.45 to 1.02)0.20 (-0.51 to 0.92)
% change by Week 52, n = 52, 650.13 (-0.67 to 0.94)-0.42 (-1.16 to 0.33)
% change by Week 78, n = 46, 560.37 (-0.54 to 1.28)-0.63 (-1.48 to 0.23)
% change by Week 104, n = 44, 53-0.40 (-1.40 to 0.61)-1.26 (-2.19 to -0.32)
% change by Week 130, n = 44, 45-0.18 (-1.12 to 0.77)-0.99 (-1.90 to -0.08)
% change by Week 156, n = 36, 40-0.42 (-1.56 to 0.73)-1.19 (-2.27 to -0.11)
Statistical analysis
  • Participants Administered VI vs Participants Administered FF/VI · Percentage change from baseline: -0.40 · 95% CI -1.16 to 0.36Overall Weeks for female
SecondaryPercentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Male Participants)

BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

Time frame:
Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Reported as:
Least squares mean · Percent change
Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Male Participants)
Percent changeParticipants Administered VIParticipants Administered FF/VI
Overall, male % change per year, n = 69, 641.41 (0.79 to 2.04)0.38 (-0.26 to 1.02)
% change by Week 26, n = 67, 641.03 (0.26 to 1.80)0.42 (-0.36 to 1.21)
% change by Week 52, n = 53, 561.91 (0.89 to 2.94)0.11 (-0.88 to 1.11)
% change by Week 78, n = 52, 452.09 (0.84 to 3.35)0.64 (-0.67 to 1.97)
% change by Week 104, n = 52, 432.72 (1.48 to 3.98)0.42 (-0.88 to 1.75)
% change by Week 130, n = 47, 381.95 (0.76 to 3.16)0.47 (-0.82 to 1.78)
% change by Week 156, n = 43, 352.96 (1.68 to 4.25)1.49 (0.13 to 2.86)
Statistical analysis
  • Participants Administered VI vs Participants Administered FF/VI · Percentage change from baseline: -1.02 · 95% CI -1.90 to -0.13Overall Weeks for Male
SecondaryPercentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Female Participants)

BMD analysis performed on log (BMD ratio to baseline) using separate repeated measures models for each gender with covariates of treatment group, age, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

Time frame:
Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Reported as:
Least squares mean · Percent change
Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Female Participants)
Percent changeParticipants Administered VIParticipants Administered FF/VI
Overall Week % change per year, n = 66, 680.17 (-0.42 to 0.77)0.12 (-0.45 to 0.70)
% change by Week 26, n = 66, 680.10 (-0.67 to 0.88)-0.19 (-0.95 to 0.58)
% change by Week 52, n = 51, 66-0.48 (-1.44 to 0.48)0.57 (-0.31 to 1.46)
% change by Week 78, n = 46, 570.33 (-0.60 to 1.26)0.25 (-0.61 to 1.11)
% change by Week 104, n = 43, 540.65 (-0.50 to 1.80)0.64 (-0.41 to 1.70)
% change by Week 130, n = 44, 491.33 (0.01 to 2.67)0.10 (-1.12 to 1.33)
% change by Week 156, n = 36, 420.80 (-0.74 to 2.36)0.10 (-1.32 to 1.53)
Statistical analysis
  • Participants Administered VI vs Participants Administered FF/VI · Percentage change from baseline: -0.05 · 95% CI -0.87 to 0.78Overall Weeks for female
SecondaryPercentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4)

BMD analysis performed on log (BMD ratio to baseline) using a repeated measures model with covariates of treatment group, age, gender, baseline BMI, visit, log baseline BMD, log baseline BMD by visit and treatment group by visit interactions. These estimates were then converted into annual changes and averaged to calculate the overall treatment estimates and difference which were used for testing non-inferiority. The analysis shown is for the "While on Treatment" estimand of the difference in percentage change from baseline per annum between FF/VI ± BMD medication/SCS (systemic corticosteroids) and VI ± BMD medication/SCS. Baseline is defined as the measurement performed at Visit 1. Percentage change is calculated as (BMD value post-Baseline divided by Baseline value) -1 multiplied by 100.

Time frame:
Baseline (Visit 1) and 26, 52, 78, 104, 130 and 156 Weeks
Reported as:
Least squares mean · Percentage Change
Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4)
Percentage ChangeParticipants Administered VIParticipants Administered FF/VI
Overall week % change per year, n=135, 1320.79 (0.36 to 1.22)0.28 (-0.15 to 0.71)
% change by Week 26, n = 133, 1320.55 (0.01 to 1.10)0.13 (-0.41 to 0.68)
% change by Week 52, n = 104, 1220.71 (0.01 to 1.42)0.40 (-0.26 to 1.07)
% change by Week 78, n= 98, 1021.20 (0.43 to 1.99)0.45 (-0.31 to 1.21)
% change by Week 104, n = 95, 971.66 (0.82 to 2.51)0.61 (-0.22 to 1.44)
% change by Week 130, n = 91, 871.70 (0.80 to 2.61)0.30 (-0.60 to 1.20)
% change by Week 156, n = 79, 771.84 (0.86 to 2.84)0.83 (-0.14 to 1.81)
Statistical analysis
  • Participants Administered VI vs Participants Administered FF/VI · Percentage change from baseline: -0.51 · 95% CI -1.11 to 0.10Overall week

Adverse events

Collected over Serious adverse events and non-serious adverse events were collected from randomization of the study until 159 weeks.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Administered VI6/142 (4.2%)42/142 (29.6%)102/142 (71.8%)
Participants Administered FF/VI4/141 (2.8%)41/141 (29.1%)116/141 (82.3%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventParticipants Administered VIParticipants Administered FF/VI
PneumoniaInfections and infestations4/14211/141
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders10/1426/141
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/1423/141
SepsisInfections and infestations0/1422/141
Femoral neck fractureInjury, poisoning and procedural complications0/1422/141
HypoxiaRespiratory, thoracic and mediastinal disorders2/1421/141
Atrial fibrillationCardiac disorders2/1420/141
Respiratory failureRespiratory, thoracic and mediastinal disorders1/1421/141
Chronic respiratory failureRespiratory, thoracic and mediastinal disorders0/1421/141
HaemoptysisRespiratory, thoracic and mediastinal disorders0/1421/141
Most frequent other events
Showing 10 of 39
Most frequent other events
EventParticipants Administered VIParticipants Administered FF/VI
NasopharyngitisInfections and infestations31/14240/141
HeadacheNervous system disorders16/14226/141
InfluenzaInfections and infestations5/14220/141
Back painMusculoskeletal and connective tissue disorders13/14220/141
BronchitisInfections and infestations16/14211/141
CoughRespiratory, thoracic and mediastinal disorders15/14213/141
ArthralgiaMusculoskeletal and connective tissue disorders14/14213/141
SinusitisInfections and infestations3/14213/141
Upper respiratory tract infectionInfections and infestations13/14212/141
Urinary tract infectionInfections and infestations12/14212/141

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Participants Administered VIParticipants Administered FF/VITotal
Mean66.0 ± 8.1964.4 ± 9.0465.2 ± 8.65
Sex: Female, Male
Sex: Female, Male(Participants)Participants Administered VIParticipants Administered FF/VITotal
Female7071141
Male7270142
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Count of participants)Participants Administered VIParticipants Administered FF/VITotal
Central/South Asian Heritage011
Black or African American112
White141139280
08

Study locations

45 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30046, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    Plymouth, Minnesota 55441, United States
  • GSK Investigational Site
    Bellevue, Nebraska 68123-4303, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406-7108, United States
  • GSK Investigational Site
    Indian Land, South Carolina 29707, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37404, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37919, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Spokane Valley, Washington 99216, United States
  • GSK Investigational Site
    Sherwood Park, Alberta T8H 0N2, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R2H 2A6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5T 3A9, Canada
  • GSK Investigational Site
    St-Charles-Borromée, Quebec J6E 2B4, Canada
  • GSK Investigational Site
    Quebec, G1V 4G5, Canada
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Neu isenburg, Hessen 63263, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 51069, Germany
  • GSK Investigational Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 12157, Germany
  • GSK Investigational Site
    Hamburg, 22143, Germany
  • GSK Investigational Site
    Alkmaar, 1815 JD, Netherlands
  • GSK Investigational Site
    Beek, 6191 JW, Netherlands
  • GSK Investigational Site
    EDE, 6716 RP, Netherlands
  • GSK Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • GSK Investigational Site
    Hengelo, 7555 DL, Netherlands
  • GSK Investigational Site
    Hoorn, 1624 NP, Netherlands
  • GSK Investigational Site
    Losser, 7581 BV, Netherlands
  • GSK Investigational Site
    Voerendaal, 6367 TM, Netherlands
  • GSK Investigational Site
    Barcelona, Catalonia 08017, Spain
  • GSK Investigational Site
    Alicante, 03004, Spain
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    L'Hospitalet de Llobregat, 08907, Spain
  • GSK Investigational Site
    Mérida (Badajoz), 06800, Spain
  • GSK Investigational Site
    Ponferrada (León), 24411, Spain
  • GSK Investigational Site
    Pozuelo De Alarcón/Madrid, 28223, Spain
  • GSK Investigational Site
    Salamanca, 37007, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Mar 2018, 49 months.

Results were first posted in Apr 2019, 1 year after primary completion.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 49 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2013
First posted
Oct 8, 2013
StartActual
Jan 28, 2014
Primary completionActual
Mar 26, 2018
CompletionActual
Mar 26, 2018
Results first posted
Apr 10, 2019
Last update
Apr 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01957150
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 8, 2013
Start date
Jan 28, 2014
Primary completion
Mar 26, 2018
Completion
Mar 26, 2018
Results posted
Apr 10, 2019
Last update
Apr 10, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion